| Status | Study |
| Completed |
Study Name: Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites Condition: Refractory Malignant Ascites Date: 2016-09-01 Interventions: Other: No intervention. Descriptive study |
| Completed |
Study Name: Impact Of Timing Of Drainage Of Massive Ascites On Operative And Post-Operative Course In Living-Donor Liver Transplant Recipients. A Prospective Randomized Controlled Trial. Condition: Massive Ascites Date: 2016-08-11 Interventions: Procedure: ultrasound guided ascitic fluid drainage |
| Recruiting |
Study Name: Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter. Condition: Malignant Ascites Date: 2016-03-20 Interventions: Device: Ascites drainage with vascular catheter. |
| Recruiting |
Study Name: To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Condition: Ascites Date: 2015-12-05 Interventions: Drug: Propranolol Propranolol |
| Terminated |
Study Name: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Condition: Malignant Ascites Date: 2015-07-01 Interventions: Drug: Intraperitoneal Bevacizumab Bevacizumab 200mg diluted in 250 ml of normal saline |
| Recruiting |
Study Name: Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology Condition: Refractory Malignant Ascites Date: 2015-06-16 Interventions: Procedure: Paracentesis Device: Tunneled I |
| Completed |
Study Name: Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites Condition: Refractory Malignant Ascites Date: 2013-05-08 Interventions: Drug: bevacizumab Other Name: Avastin |
| Completed |
Study Name: ALFApump System Versus Standard of Care in Ascites Treatment Condition: Refractory or Recurrent Ascites Date: 2012-01-31 Interventions: Device: ALFApump removal of ascites |
| Completed |
Study Name: Tolvaptan for Ascites in Cirrhotic Patients Condition: Ascites Cirrhosis Date: 2011-02-07 Interventions: Drug: Tolvaptan Oral administration once daily Dosage will range from 15 mg to 30 mg |
| Completed |
Study Name: Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers Condition: Malignant Ascites Gastrointestinal Cancers Date: 2010-09-09 Interventions: Drug: Bevacizumab Patients wil |